Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis

M Ghadiri, A Rezk, R Li, A Evans, PS Giacomini… - Scientific Reports, 2020 - nature.com
Biomarkers predicting fingolimod (FTY) treatment response in relapsing-remitting multiple
sclerosis (RRMS) are lacking. Here, we performed extensive functional immunophenotyping
using multiparametric flow cytometry to examine peripheral immune changes under FTY
treatment and explore biomarkers of FTY treatment response. From among 135 RRMS
patients who initiated FTY in a 2-year multicentre observational study, 36 were classified as
'Active'or 'Stable'based on clinical and/or radiological activity on-treatment. Flow cytometric …

[引用][C] Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis. Sci Rep 10 (1): 356

M Ghadiri, A Rezk, R Li - 2020
以上显示的是最相近的搜索结果。 查看全部搜索结果